|Day Low/High||3.83 / 3.99|
|52 Wk Low/High||2.15 / 9.88|
Data From Successful Placebo-Controlled Study to be Submitted to Regulatory Authorities to Support STENDRA Label Amendment for 15-Minute Efficacy Claim
First Manhattan Co., the beneficial owner of approximately 9.
In trading on Thursday, shares of Vivus, Inc. crossed above their 200 day moving average of $14.90, changing hands as high as $15.04 per share.
Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.
First Guidelines to Incorporate Anti-Obesity Medications as Recommended Treatment for Cardiometabolic Diseases
Vivus' Qsymia will now be available at retail pharmacies.
A favorable FDA ruling on Qsymia's distribution is not enough for First Manhattan.
The DEA is taking its sweet time determining the abuse potential for Arena's weight-loss pill.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.